Journal Scan

Maralixibat shows clinically meaningful improvements in cholestasis in ALGS

Children with Alagille syndrome (ALGS) treated with Maralixibat experience durable and clinically meaningful improvements in cholestasis, according to a study. In the randomized withdrawal period of the phase 2b ICONIC study, 29 children with ALGS who had elevated serum bile acid (sBA) levels and intractable pruritus received maralixibat 380 μg/kg...